Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1043-1059 |
| Number of pages | 17 |
| Journal | Journal of Alzheimer's Disease |
| Volume | 108 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Dec 2025 |
Keywords
- Alzheimer's disease
- amyloid
- amyloid biomarker study
- cerebrospinal fluid
- lifestyle
- positron emission tomography
Access to Document
- 10.1177/13872877251379083Licence: CC BY-NC
Fingerprint
Dive into the research topics of 'Associations of lifestyle factors with amyloid pathology in persons without dementia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Alzheimer's Disease, Vol. 108, No. 3, 01.12.2025, p. 1043-1059.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Associations of lifestyle factors with amyloid pathology in persons without dementia
AU - Oomens, Julie E.
AU - Vos, Stephanie J.B.
AU - Maserejian, Nancy N.
AU - Boada, Mercè
AU - Didic, Mira
AU - Engelborghs, Sebastiaan
AU - Fladby, Tormod
AU - van der Flier, Wiesje M.
AU - Frisoni, Giovanni B.
AU - Fröhlich, Lutz
AU - Gill, Kiran Dip
AU - Grimmer, Timo
AU - Hort, Jakub
AU - Itoh, Yoshiaki
AU - Iwatsubo, Takeshi
AU - Klimkowicz-Mrowiec, Aleksandra
AU - Landau, Susan M.
AU - Lee, Dong Young
AU - Lleó, Alberto
AU - Martinez-Lage, Pablo
AU - de Mendonça, Alexandre
AU - Meyer, Philipp T.
AU - Parchi, Piero
AU - Pardini, Matteo
AU - Parnetti, Lucilla
AU - Popp, Julius
AU - Rami, Lorena
AU - Reiman, Eric M.
AU - Rinne, Juha O.
AU - Rodrigue, Karen M.
AU - Sánchez-Juan, Pascual
AU - Santana, Isabel
AU - Scarmeas, Nikolaos
AU - Scheltens, Philip
AU - Skoog, Ingmar
AU - Sperling, Reisa A.
AU - Stern, Yaakov
AU - Villeneuve, Sylvia
AU - Waldemar, Gunhild
AU - Wiltfang, Jens
AU - Zetterberg, Henrik
AU - Alcolea, Daniel
AU - Allegri, Ricardo F.
AU - Altomare, Daniele
AU - Bateman, Randall J.
AU - Baiardi, Simone
AU - Baldeiras, Ines
AU - Blennow, Kaj
AU - Handels, Ron
AU - Ramakers, Inez H.
AU - Alzheimer's Disease Neuroimaging Initiative (ADNI)
AU - A4 Study group
AU - Dominantly Inherited Alzheimer Network (DIAN)
AU - European Prevention of Alzheimer’s Dementia (EPAD) consortium
AU - Fundació ACE Healthy Brain Initiative (FACEHBI)
AU - Japan Alzheimer's Disease Neuroimaging Initiative (J-ADNI)
AU - Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer’s disease (KBASE)
AU - Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease (PREVENT-AD) research group
N1 - Funding Information: Dr Teunissen reported receiving research support from the European Commission (Marie Curie International Training Network and Joint Program for Neurodegenerative Diseases grants), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association, and ABOARD (A Personalized Medicine Approach for Alzheimer's Disease), which is a public-private partnership supported by ZonMW, Alzheimer Nederland, Health Holland, Gieskes-Strijbisfonds, and Edwin Bouw Fonds; having a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly and Company; performing contract research or receiving grants from AC Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai Inc, PeopleBio, Roche, Toyama, and Vivoryon; serving on editorial boards of Medidact Neurologie/ Springer, Alzheimer Research and Therapy, and Neurology: Neuroimmunology & Neuroinflammation; and being editor of a neuromethods book from Springer. Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Amyloid Biomarker Study is supported by Biogen. Members of the following groups contributed to this article and are listed in online Appendix 1: Alzheimer's Disease Neuroimaging Initiative (ADNI; protocol in Supplemental Material 1), A4 Study group, Dominantly Inherited Alzheimer Network (DIAN), Fundaci\u00F3 ACE Healthy Brain Initiative (FACEHBI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's disease (KBASE), and the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) research group. Funding Information: Dr Boada reported funding from the Instituto de Salud Carlos III (ISCIII) Acci\u00F3n Estrat\u00E9gica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirecci\u00F3n General de Evaluaci\u00F3n and the Fondo Europeo de Desarrollo Regional (FEDER\u2014Una manera de hacer Europa) grant PI17/01474; consulting for for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier, receiving fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier and grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU. Funding Information: Dr van der Flier reports research programs have been funded by ZonMW, NWO, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health\u223CHolland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. WF holds the Pasman chair. She is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health\u223CHolland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). All funding is paid to her institution. She has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, NovoNordisk, European Brain Council. All funding is paid to her institution. She is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. All funding is paid to her institution. She participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. She is a member of the steering committee of PAVE, and Think Brain Health. She was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. Funding Information: Dr Sperling reported receiving honorarium for consulting from AC Immune, Acumen, Alnylam, Cytox, Genentech, Janssen, JOMDD, Oligomerix, Neuraly, Neurocentria, Renew, Prothena, and Shionogi; reported receiving research funding from the National Institute on Aging (NIA), Alzheimer's Association, Eisai Inc, Eli Lilly and Company, and Janssen; and reported the following financial relationships for her spouse (Dr Keith Johnson): Cerveau, Janssen, AC Immune, and Novartis. Funding Information: Dr Marqui\u00E9 reported funding from the Instituto de Salud Carlos III (ISCIII) Acci\u00F3n Estrat\u00E9gica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirecci\u00F3n General de Evaluaci\u00F3n and the Fondo Europeo de Desarrollo Regional (FEDER\u2014Una manera de hacer Europa) grant PI19/00335, consulting for F. Hoffmann-La Roche Ltd and participating in advisory boards from Araclon Biotech-Grifols. Funding Information: Dr Ossenkoppele has received research funding from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer's fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden (all paid to the institutions).R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, and has given lectures in symposia sponsored by GE Healthcare. He is an advisory board member for Asceneuron and Bristol Myers Squibb. All the aforementioned has been paid to the institutions. He is an editorial board member of Alzheimer's Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging. Funding Information: Dr Ruiz reported receiving support from Centro de Investigaci\u00F3n Biom\u00E9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III (ISCIII); the EU/European Federation of Pharmaceutical Industries and Associations (EFPIA) Innovative Medicines Initiative Joint Undertaking; grants from the EXIT (Exosomes Isolation Tool with Nanofluidic Concentration Device) project, EU Euronanomed3 Program, and PREADAPT project; grant from the Joint Program for Neurodegenerative Diseases; and research funding from ISCIII Acci\u00F3n Estrat\u00E9gica en Salud, which was integrated in the Spanish National RCDCI Plan and financed by a grant from ISCIII-Subdirecci\u00F3n General de Evaluaci\u00F3n and the Fondo Europeo de Desarrollo Regional (FEDER; Una manera de hacer Europa) by Fundaci\u00F3n Bancaria La Caixa and Gr\u00EDfols SA (GR@ACE project). Funding Information: The remaining authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Dr Jansen reported funding from ZonMw, Alzheimer Nederland, St. Rinsum-Ponssen and research support from Biogen (paid to institution). Funding Information: Dr Rami reported funding from the Instituto de Salud Carlos III (ISCIII) Acci\u00F3n Estrat\u00E9gica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirecci\u00F3n General de Evaluaci\u00F3n and the Fondo Europeo de Desarrollo Regional (FEDER\u2014Una manera de hacer Europa) grant PI19/00745. Funding Information: Dr Altomare received funding by the Fondation Recherche Alzheimer, and the Swiss National Science Foundation (project CRSK-3_196354 / 1). Publisher Copyright: © The Author(s) 2025. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PY - 2025/12/1
Y1 - 2025/12/1
N2 - Background: The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective: The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology. Methods: For this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology. Results: We included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were APOE e4 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were APOE e4 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR = 0.77, 95%CI 0.66–0.89, p < 0.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR = 0.85, 95%CI 0.73–0.99, p = 0.029; OR = 0.62, 95%CI 0.45–0.86, p = 0.004). Conclusions: In NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.
AB - Background: The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective: The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology. Methods: For this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology. Results: We included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were APOE e4 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were APOE e4 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR = 0.77, 95%CI 0.66–0.89, p < 0.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR = 0.85, 95%CI 0.73–0.99, p = 0.029; OR = 0.62, 95%CI 0.45–0.86, p = 0.004). Conclusions: In NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.
KW - Alzheimer's disease
KW - amyloid
KW - amyloid biomarker study
KW - cerebrospinal fluid
KW - lifestyle
KW - positron emission tomography
U2 - 10.1177/13872877251379083
DO - 10.1177/13872877251379083
M3 - Article
SN - 1387-2877
VL - 108
SP - 1043
EP - 1059
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 3
ER -